Turkish Journal of Nephrology
Original Article

Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium with the Concomitant Use of Proton Pump Inhibitors in Patients who Received Kidney Transplant


Department of Clinical Pharmacy, Ankara University Faculty of Pharmacy, Ankara, Turkey


Department of Nephrology, Ankara University Faculty of Medicine, Ankara, Turkey


Department of Pharmacology, Ankara University Faculty of Pharmacy, Ankara, Turkey

Turkish J Nephrol 2022; 31: 348-354
DOI: 10.5152/turkjnephrol.2022.2168103
Read: 306 Downloads: 162 Published: 02 December 2021

Objective: This study aims to describe and compare the transplant outcomes of kidney transplant (KTx) patients who received either mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) with the concomitant use of proton pump inhibitors (PPIs). 

Materials and Methods: This was a 9-year retrospective observational study conducted between 1 January 2011 and 31 December 2019 at ... Hospital, Nephrology Department, … University Faculty of Medicine.

Results: Among 349 KTx patients, 290 were eligible for the study with aged [median (interquartile range (IQR))] 41 (33-50) years in the MMF group and 41 (31-50) years in the EC-MPS group. More than half of them were male (54% in MMF vs. 60% in EC-MPS groups) and the majority received a living transplant (79% in both). There was no statistically significant difference in transplant outcomes including protein/creatinine ratio [(median (IQR)): 150 (2-308) vs. 153 (58-397), p=0.742], creatinine doubling (8% vs. 10%, p=0.589), change in medications (46% vs. 48%, p=0.775), delayed graft function (8% vs. 14%, p=0.153), biopsy-proven acute rejection (14% vs. 18%, p=0.327), graft loss (7% vs. 10%, p=0.351) and overall mortality (4% vs. 6%, p=0.337) among the patient groups who received either MMF or EC-MPS, respectively.

Conclusion: The transplant outcomes including graft survival, BPAR, graft loss, or delayed graft function of the KTx patients who received MMF or EC-MPS with PPIs were similar. Therefore, PPIs and MMF or EC-MPS can be prescribed together safely with appropriate follow-up intervals.

Cite this article as: Selçuk A, Pehlivanlı A, Eyüpoğlu Ş, Özçelikay AT, Şengül Ş. Mycophenolate mofetil and enteric-coated mycophenolate sodium with the concomitant use of proton pump inhibitors in patients who received kidney transplant. Turk J Nephrol. 2022;31(4):348-354.

EISSN 2667-4440